Last reviewed · How we verify
Intravenous Fentanyl 25 mcg
At a glance
| Generic name | Intravenous Fentanyl 25 mcg |
|---|---|
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Increased respiratory rate
- Decreased heart rate
- Decreased respiratory rate
- Increased blood pressure
- Nausea
- Headache
- Increased heart rate
- Decreased blood pressure
- Erythema
- Abdominal cramping
- Pain, swelling, bruising, abrasions, erythema at IV catheter site
Key clinical trials
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
- Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration (PHASE3)
- Intravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy (PHASE4)
- Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation (PHASE2)
- Pilot Study on Pairing Sedation Strategies and Weaning (NA)
- Serratus Posterior Superior Plane Block for Postoperative Pain in Cardiac Surgery (NA)
- Preoperative Use of Peripheral Nerve Blocks in Elderly Patients With Hip Fractures (PHASE4)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Fentanyl 25 mcg CI brief — competitive landscape report
- Intravenous Fentanyl 25 mcg updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI